Mediaboss Marketing

Megan Fox still hates social media and no longer has a Twitter account.

The star began tweeting on the social networking site last week under the @meganfox handle.

Apparently Megan doesnt understand why she joined in the first place, as she never really had much interest in the Internet.

"Some of you may or may not have noticed by now that my Twitter account has been shut down," she wrote on her Facebook page Thursday.

"I thought that 2013 might be the year that I finally blossomed into a social networking butterfly, but as it turns out, I still hate it.

"Love you guys but I will just never be that girl. Facebook is as much as I can handle. I'm sorry."

Megan didnt appear to get the hang of Twitter initially.

She may have lost interest in the social networking platform almost immediately after she signed up for it.

"I'm incredibly late to the party but I'm here nonetheless, so what now?" her first tweet read.

The 26-year-old actress welcomed her first child with husband Brian Austin Green, Noah, into the world at the end of September this year.

More:
Megan Fox not a ‘social networking butterfly’

Washington, Jan 10 (ANI): An observation on the social interactions of a troop of free-ranging monkeys and an analysis of their family trees has found signs of natural selection affecting the behavior of the descendants.

Rhesus macaques who had large, strong networks tended to be descendants of similarly social macaques, according to a Duke University team of researchers.

And their ability to recognize relationships and play nice with others also won them more reproductive success.

"If you are a more social monkey, then you're going to have greater reproductive success, meaning your babies are more likely to survive their first year," post-doctoral research fellow Lauren Brent, who led the study said.

"Natural selection appears to be favoring pro-social behavior," he said.

The analysis combined sophisticated social network maps with 75 years of pedigree data and some genetic analysis.

The monkeys are a free-ranging population of macaques descended from a 1938 release of monkeys from India on undeveloped 38-acre Cayo Santiago Island, off the eastern coast of Puerto Rico. They live in a natural setting with little human intervention other than food provisioning.

Field researchers who had learned to identify each of the nearly 90 monkeys on sight carefully logged interactions between individuals in 10-minute episodes over a two-year span.

They compiled four or five hours of data per individual, logging grooming, proximity and aggression.

From that, the team built web-like network maps to analyze pro-social and anti-social interactions.

Continued here:
Social networking a family trait in monkeys

ATLANTA, GA--(Marketwire - Jan 10, 2013) - GeoVax Labs, Inc. ( OTCQB : GOVX ), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, announced it has completed enrollment in a nine-patient Phase 1/2 clinical trial testing the safety, immunogenicity and ability of its DNA/MVA vaccine to elicit protective immune responses in HIV-infected individuals.

The primary goal of this study is to document the safety and immunogenicity of GeoVax's vaccine in HIV-positive patients with well-controlled infections using oral HIV drug medication. Following vaccination, the trial includes a short period of drug-interruption to evaluate the ability of the vaccine to control the infection in the absence of continuing drug therapy. The Phase 1/2 trial (designated GV-TH-01) consists of priming with a recombinant DNA vaccine followed by boosting with a recombinant modified vaccinia Ankara (MVA) vaccine. The vaccine regimen elicits both antiviral antibody that can block infection and antiviral T cells that can recognize and kill infected cells. The trial is being conducted at the AIDS Research Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama, Birmingham and the AIDS Research Alliance of Los Angeles.

Robert McNally, Ph.D., President and CEO of GeoVax, stated, "This pilot study is our first trial investigating use of a therapeutic vaccine to address the need for a treatment that is better tolerated and less costly than the HIV oral medications currently available. We anticipate having meaningful data from the program later this year."

Harriet Robinson, GeoVax's Chief Scientific Officer, commented, "Our next step planned for our therapeutic vaccine development program is a Phase 1 clinical trial to investigate the use of our vaccine in combination with standard-of-care drug therapy in young adults. This trial will likely be conducted by the International Maternal Pediatric Adolescent AIDS Clinical Trial Group (IMPAACT). One of the hopes for therapeutic vaccination is that combining a vaccine with drugs will allow the eradication of virus from an infected individual. Drugs primarily prevent infection whereas a vaccine can both block infection and kill infected cells."

About GeoVax

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from a Phase 1 study supported a Phase 2a trial that was completed in the 3rd quarter of 2012.

GeoVax's 2nd generation preventive vaccine is currently in phase 1 testing and is planned to progress to phase 2 efficacy testing, given safety and immunogenicity are as expected. Overall, the GeoVax vaccine, in various doses and combinations, has been tested in close to 500 humans. GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit http://www.geovax.com.

About HIV/AIDS

HIV infection, which can lead to AIDS, is a pandemic that can affect anyone, regardless of race, gender, age, or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with HIV. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.

For more Information, please visit http://www.geovax.com.

Go here to see the original:
GeoVax Announces Enrollment Completion for Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine

Your look at the five biggest and most buzz-worthy stories of the morning.

1. Killer Whales Trapped Under Sea Ice

A community in Quebec is calling for outside help to free about a dozen killer whales that are trapped under a large stretch of sea ice. Locals say the mammals have gathered around a hole in the ice to get oxygen.

2. Flu Prompts Boston Public Health Emergency

An early flu season has prompted a public health emergency in Boston, where 700 people have been diagnosed with the virus. Four Boston residents - all elderly - have died from the flu. At this time last year, the city had only seen 70 cases of influenza.

3. China Snubs U.S. Investor Fraud Request

The Chinese government has snubbed a U.S. request to help crack down a string of alleged investment frauds that have cost Americans billions of dollars, according to Securities and Exchange Commission Chairman Mary Schapiro. The lack of cooperation has stunted efforts to recoup investor losses.

4. Monopoly Tokens to be Eliminated

One of eight iconic Monopoly tokens will soon be eliminated. Hasbro is holding a Facebook contest to determine which one of the tokens that identifies players will be eliminated so they can introduce a new one.

5. Dog Treats Taken Off Market

Visit link:
5 Things to Know This Morning

Jan. 10, 2013, 11:49 a.m.

A highly contagious virus that is deadly to dogs has appeared in western Queensland, with three animals infected in a week.

Cases of canine parvovirus reappeared at veterinary clinics in Mount Isaover the weekend, sparking calls for residents to take precautionary measure to protect their pets.

Paws, Hoofs and Claws Charity president Sue Carson admitted three dogs with the potentially fatal virus to the veterinary last week.

Bear, a four-month old collie cross and two newborn French-Boxer cross puppies were still recovering from the illness.

Mrs Carson said the highly contagious virus existed anywhere infected animals had been and could lay dormant in the ground for morethan a year.

"It's passed through bodily fluids like urine and faeces," she said.

"Its not just in backyards, it can affect parks and footpaths too."

Mrs Carson said people new to Mount Isa or thinking about purchasing a new pet needed to be wary of where they took their dogs.

"It's a timely warning for the residents of Mount Isa," she said.

Read more from the original source:
Killer virus sparks warning Save